Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion [0.03%]
美托洛尔反应的个体差异：细胞色素P450 2D6、药物相互作用和表型转换的影响
Bayan Azizi,David E Lanfear,Jasmine A Luzum
Bayan Azizi
Metoprolol, a β1-selective blocker, is widely used for treating cardiovascular and non-cardiovascular conditions. Its pharmacokinetics (PK) and pharmacodynamics (PD) vary significantly between individuals, in part due to CYP2D6 genetic pol...
Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight [0.03%]
塞普替尼治疗液态活检发现的RET阳性晚期胰腺癌的一例报告
Tarek Assi,Tania Moussa,Cendrella Bou-Orm et al.
Tarek Assi et al.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis and limited effective treatments. Standard chemotherapy offers modest survival benefits, and actionable genetic alterations are rare. RET gene fusions...
Correction [0.03%]
改正的方法
Published Erratum
Pharmacogenomics. 2025 Dec 10:1. DOI:10.1080/14622416.2025.2601450 2025
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis [0.03%]
全外显子组测序识别出与抗结核药物性肝损伤相关的PPIX代谢通路罕见变异
Yu Wu,Lihuan Lu,Fei Wang et al.
Yu Wu et al.
Aims: To screen and validate rare variants in the protoporphyrin IX (PPIX)-metabolizing pathway associated with anti-tuberculosis drug-induced hepatitis (AT-DIH). ...
Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe [0.03%]
津巴布韦胃肠肿瘤患者支持性照护中实施药物基因组学的应用前景与挑战
Tinashe Adrian Mazhindu,Ntokozo Ndlovu,Margaret Z Borok et al.
Tinashe Adrian Mazhindu et al.
Introduction: Supportive care in oncology aims to prevent and manage cancer-related side effects. This study reviews supportive medications for gastrointestinal cancer patients, analyzes usage patterns, biomarker frequenc...
Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes [0.03%]
蒽环类-环磷酰胺-紫杉烷化疗的药物基因组学：CYP多态性和BMI对乳腺癌治疗结果的影响
Tanuma Mistry,Partha Nath,Neyaz Alam et al.
Tanuma Mistry et al.
Aims: Sequential Anthracycline-Taxane chemotherapy is standard treatment for BC. This study examines the combined impact of low BMI and CYP polymorphisms on treatment response. ...
Genetic polymorphisms of VEGFR2 and FGFR2 genes are associated with exposure to sunitinib and cardiovascular toxicity [0.03%]
VEGFR2和FGFR2基因多态性与舒尼替尼暴露及心血管毒性相关性分析
Litaty C Mbatchi,Fanny Leenhardt,Bob-Valéry Occean et al.
Litaty C Mbatchi et al.
Purpose: Sunitinib is a multikinase inhibitor used to treat metastatic renal cell carcinoma (mRCC), with an inter-individual variability of pharmacokinetics and toxicity. Our goal was to assess associations between the ph...
From genomics to clinic: the transformative impact of AI in pharmacogenomics and personalized medicine [0.03%]
从基因组学到临床：人工智能在药物基因组学和个性化医学中的变革性影响
Anantha Lakshmi Jakka,Ripsy Merrin Chacko,Mallikarjun Vasam et al.
Anantha Lakshmi Jakka et al.
At the crossroads of genomics and pharmacology, pharmacogenomics is revolutionizing healthcare by tailoring drug therapies to individual genetic profiles thereby reducing the risk of adverse drug reactions and propelling the field of precis...
Cancer genetics and response to oncolytic virus treatment for ovarian cancer [0.03%]
卵巢癌的癌症遗传学和溶瘤病毒治疗反应
Erin L Fletcher,Alison O Cudmore,Barbara C Vanderhyden
Erin L Fletcher
Ovarian cancers (OCs) are often defined as poorly immunogenic tumors that have low response rates to current immunotherapies and frequently develop resistance to chemotherapies. Oncolytic viruses (OVs) are an emerging therapeutic approach t...
Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study [0.03%]
巴西儿童急性淋巴细胞 leukemia聚乙二醇天冬酰胺酶毒性药理基因标记物的多中心前瞻性队列研究见解
Daiane Keller Cecconello,Klerize Anecely de Souza Silva,Evelin Cristine Mendonça de Senna et al.
Daiane Keller Cecconello et al.
Aims: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Although PEG-asparaginase (PEG-ASNase) is a key drug in treatment, hypersensitivity reactions, pancreatitis, and silent inactivation remain maj...